Floatz logo

9mw2821

Urothelial Carcinoma Bladder

Mabwell (Shanghai) Bioscience Co., Ltd.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

37 Active assets in the Urothelial Carcinoma Bladder cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB
Atezolizumab
KaliVir Immunotherapeutics
Phase 3BB
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB
Nivolumab
Nagoya University
Phase 3BB

View all 50 →

Same molecule, other indications

9mw2821 is also rated in:

breast neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
renal pelvis/ureter urothelial carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Hormone Receptor Positive TumorDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →